Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Identifying Therapeutic Targets for Chemotherapy-Resistant Glioblastoma
Scientific Advances

Identifying Therapeutic Targets for Chemotherapy-Resistant Glioblastoma

By Melissa RohmanJul 21, 2022
Share
Facebook Twitter Email

Investigators have discovered novel cellular pathways behind chemotherapy-resistant glioblastoma cells and a potential biomarker, paving the way for new therapeutic targets, according to findings published in Science Advances.

Deanna Tiek, PhD, a postdoctoral fellow in the laboratory of Shi-Yuan Cheng, PhD, was the lead author of the study published in Science Advances.

The lead author of the study was Deanna Tiek, PhD, a postdoctoral fellow in the laboratory of Shi-Yuan Cheng, PhD, a professor in the Ken and Ruth Davee Department of Neurology.  Cheng, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was a co-author.

Over the last two decades, the chemotherapeutic drug temozolomide (TMZ) has been the standard of care for patients with glioblastoma (GBM). This therapy targets guanine nucleotides, one of the four main building blocks of DNA.

Unfortunately, all patients with GBM will eventually develop TMZ resistance and are given an overall survival rate of 14 to 16 months, underscoring the dire need for more second-line treatments.

In the current study, Tiek and her team aimed to identify targetable cellular pathways in TMZ-resistant GBM cells. Using whole-genome sequencing and nanopore full-length RNA sequencing technologies, the investigators studied changes in G-rich G-quadruplexes (known as G4s, or, four guanines stacked on top of each other) and splice sites (alterations in DNA that occur at the boundary of an exon and an intron) that occur during TMZ resistance.

“Since TMZ targets guanines and a lot of other brain disorders have disruptions in these secondary structures of DNA — most commonly G-quadruplexes — we wanted to see if that was also happening due to TMZ treatment,” Tiek said.

Shi-Yuan Cheng, PhD, a professor in the Ken and Ruth Davee Department of Neurology’s Division of Neuro-Oncology, was a co-author of the study.

They discovered that the TMZ-resistant GBM cells contained guanine mutations that disrupt G-rich G4s and splice sites, disrupting alternative RNA splicing, a gene’s ability to code for multiple proteins.

To their surprise, they also found the RNA-binding protein EWSR1— a biomarker that’s present in many neurodegenerative diseases — aggregated in TMZ-resistant glioblastoma cells. This also led to the development of a novel splicing kinase inhibitor, CLK2i, which the investigators showed specifically targeted TMZ-resistant GBM cells.

With these findings in hand, Tiek is now investigating global changes in other regions of the genome that are disrupted by guanine changes and trying to determine which upstream pathways could be targeted to prevent the aggregation of RNA binding proteins.

“We didn’t look for a gene that was mutated and then try to target that mutation, but rather if you have these broad mutations in a lot of splice sites, then there is an upstream regulator that we can target,” Tiek said.

This work was supported by the National Institutes of Health grants K00 CA234799, T32 CA009686 and R01 NS115403, a student research grant from the Medical Center Graduate Student Organization, and the Lou and Jean Malnati Brain Tumor Institute of the Lurie Cancer Center.

Cancer Neurology Neurology and Neuroscience Research
Share. Facebook Twitter Email

Related Posts

Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023

Weintraub Appointed to Illinois Supreme Court Commission on Elder Law

Mar 28, 2023

Comments are closed.

Latest News

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023

Weintraub Appointed to Illinois Supreme Court Commission on Elder Law

Mar 28, 2023

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.